Skip to main content
. Author manuscript; available in PMC: 2009 Oct 1.
Published in final edited form as: Semin Immunol. 2008 Jun 9;20(5):267–275. doi: 10.1016/j.smim.2008.04.001

Figure 2.

Figure 2

Volume of subcutaneous B16 melanoma tumors transfected with a murine homologue of EGFRvIII, msEGFRvIII, in C57BL/6J mice treated with anti-EGFRvIII mouse MAb Y10, (IgG2a) and L8A4 (IgG1). Mice were treated i.p. on day 0 with 500 μg of anti-EGFRvIII MAbs or isotype matched control MAbs, followed by 200 μg of MAb every other day thereafter for 20 days. Treatment with isotype control MAbs failed to inhibit tumor growth. Mice treated with L8A4 remained tumor free until treatment was stopped and the tumors then grew at a rate equal to untreated tumors. Mice treated with Y10 were protected from tumor growth even after MAb therapy was stopped.

HHS Vulnerability Disclosure